


Supplementary Fig. S3. Clinical benefit does not correlate with ctDNA *ESR1* mutant allele frequency (MAF) baseline levels or dynamics upon treatment, or with baseline ER and PR protein levels by IHC in tumor tissue. **(A)** Baseline levels of *ESR1* MAF, ER H-score, and PR H-score in patients with and without clinical benefit. **(B)** Number and percentage of patients with and without clinical benefit subgrouped by decreased or increased *ESR1* MAF in the first post-baseline sample (either Cycle 3 - Day 1 or end-of-treatment).

A.



B.

